Vitamin D in the prevention of exacerbations of asthma in preschoolers (DIVA): Protocol for a multicentre randomised placebo-controlled triple-blind trial

Megan E. Jensen  
*School of Medicine and Public Health*

Francine M. Ducharme  
*University of Montreal*

Nathalie Alos  
*University of Montreal*

Geneviève Mailhot  
*University of Montreal*

Benoît Mâssé  
*CHU Sainte-Justine - Le Centre Hospitalier Universitaire Mère-Enfant*

*See next page for additional authors*

Follow this and additional works at: [https://ir.lib.uwo.ca/paedpub](https://ir.lib.uwo.ca/paedpub)

**Citation of this paper:**  
Jensen, Megan E.; Ducharme, Francine M.; Alos, Nathalie; Mailhot, Geneviève; Mâsse, Benoît; White, John H.; Sadatsafavi, Mohsen; Khamessan, Ali; Tse, Sze Man; Alizadehfar, Reza; Bock, Dirk E.; Daigneault, Patrick; Lemire, Chantal; Yang, Connie; and Radhakrishnan, Dhenuka, "Vitamin D in the prevention of exacerbations of asthma in preschoolers (DIVA): Protocol for a multicentre randomised placebo-controlled triple-blind trial" (2019). *Paediatrics Publications*. 838.  
[https://ir.lib.uwo.ca/paedpub/838](https://ir.lib.uwo.ca/paedpub/838)
**BMJ Open**

**Vitamin D in the prevention of exacerbations of asthma in preschoolers (DIVA): protocol for a multicentre randomised placebo-controlled triple-blind trial**


**ABSTRACT**

**Introduction** Preschoolers have the highest rate of emergency visits and hospitalisations for asthma exacerbations of all age groups, with most triggered by upper respiratory tract infections (URTIs) and occurring in the fall or winter. Vitamin D insufficiency is highly prevalent in Canadian preschoolers with recurrent asthma exacerbations, particularly in winter. It is associated with more URTIs and, in patients with asthma, more oral corticosteroid (OCS) use. Although evidence suggests that vitamin D supplements significantly decrease URTIs and asthma exacerbations requiring OCS, there is insufficient data in preschoolers. This study aims to determine the impact of vitamin D supplementation on exacerbations requiring OCS, in preschoolers with recurrent URTI-induced asthma exacerbations.

**Methods and analysis** This is a phase III, randomised, triple-blind, placebo-controlled, parallel-group multicentre trial of vitamin D₃ supplementation in children aged 1–5 years, with asthma triggered by URTIs and a recent history of frequent URTIs and OCS use. Children (n=865) will be recruited in the fall and early winter and followed for 7 months. They will be randomised to either the (1) intervention: two oral boluses of 100 000 international unit (IU) vitamin D₃ (3.5 months apart) with 400 IU vitamin D₃ daily; or (2) control: identical placebo boluses with daily placebo. The primary outcome is the number of exacerbations requiring OCS per child, documented by medical and pharmacy records. Secondary outcomes include number of laboratory-confirmed viral URTIs, exacerbation duration and severity, parent functional status, healthcare use, treatment deintensification, cost and safety.

**Ethics and dissemination** This study has received ethical approval from all sites. Results will be disseminated via international conferences and manuscripts targeting paediatricians and respiratory physicians, and to families of asthmatic children via our Quebec parents–partners outreach programme. If proven effective, findings may markedly influence the management of URTI-induced asthma in high-morbidity preschoolers and could be directly applied into practice with an update to clinical guidelines.

**Strengths and limitations of this study**

- This multicentre randomised controlled trial will be the largest paediatric study testing the impact of high-dose vitamin D supplementation, compared with placebo, as adjunct to inhaled corticosteroids, in preschool-aged children with predominantly viral-induced asthma.
- This trial uses a pragmatic patient selection and easily applicable intervention to maximise subsequent implementation in practice.
- The main outcome, the number of exacerbations treated with rescue oral corticosteroids, was selected by parents–partners as clinically meaningful, which can be successfully ascertained by pharmacy and medical records in all randomised participants: it is likely to change practice if a 25% reduction is documented.
- Because of the variability in diet, vitamin D supplement use, sun exposure and skin colour, it is impossible to control all factors that may affect circulating vitamin D levels; however, it is expected that these factors will be balanced across groups due to randomisation and recruitment only in fall and early winter.
- Despite the ethical requirement of allowing eligibility for children taking up to 400 IU of supplemental vitamin D, there is a low risk of dilution of effect, given that the average dietary and supplemental intake in the target population is 60% lower than recommended.

**INTRODUCTION**

Preschool-aged children have the highest rate of emergency department (ED) visits...
and hospitalisations due to wheeze/asthma among all age groups, with annual ED visit rates of 23–42/1000; on average, one in three are hospitalised following an ED visit. Most exacerbations are triggered by viral upper respiratory tract infections (URTIs), which occur frequently in preschool-aged children. URTIs cause more severe exacerbations than other triggers, and are associated with poorer response to oral corticosteroids (OCS). Although daily or pre-emptive high-dose inhaled corticosteroids (ICS) as monotherapy have been identified as effective management strategies for preschool asthma, 50% still require rescue OCS within 6 months. Yet, in case of treatment failure, there is no official recommendation for step-up therapy as there is only one published trial in preschool-aged children testing the benefit of adjunct therapy to ICS. The dearth in knowledge to manage high-morbidity preschoolers with ongoing exacerbations despite ICS monotherapy underlines the crucial need for new prevention strategies.

A 2016 systematic review of randomised controlled trials (RCT) testing vitamin D supplementation in patients with asthma found vitamin D reduced the rate of exacerbations requiring OCS by 36% (RR 0.64, 658 adults/22 preschoolers) and acute-care visits/hospitalisations by 61% (OR 0.39, 664 adults/277 school-aged children/22 preschoolers). Due to the under-representation of preschoolers and participants with moderate/severe asthma, considerable heterogeneity in vitamin D dosing and ICS co-intervention, and the paucity of trials, there was insufficient power to explore subgroup differences; it thus remains unclear whether patient (eg, age, baseline serum 25-hydroxyvitamin D (25OHD) level, genetic variation) or treatment (eg, vitamin D schedule, ICS use) characteristics modify the magnitude of benefit. Subsequent paediatric trials using various populations, interventions and outcomes led to conflicting results. Clearly, there is a need for an adequately powered, confirmatory efficacy trial, to determine if vitamin D supplementation, as adjunct to ICS, reduces exacerbations requiring OCS in preschoolers with viral-induced asthma, irrespective of serum baseline 25OHD.

Exploration of potential mechanisms of action would further elucidate the role of vitamin D in asthma. A protective effect of vitamin D on upper (OR 0.64) and lower (OR 0.58) respiratory infections, and in school-aged children with viral-induced asthma (RR 0.26), has been previously reported. However, the absence of laboratory confirmation of infection in most trials raises the possibility of outcome misclassification: only one trial objectively documented infection (influenza A), reporting a significant reduction (RR 0.58) in exacerbations with vitamin D supplements. In most tissues, infection or allergen exposure induce the expression of enzyme CYP27B1 that converts 25OHD into active 1,25-dihydroxyvitamin D; the latter binds to nuclear vitamin D receptor, which regulates the transcription of over 1000 genes, including several associated with bronchial smooth muscle cells, explaining the observed inverse relationship between serum 25OHD and airway reactivity. An immune-modulating and synergistic effect of vitamin D with ICS on airway inflammation may also exist, with a paediatric RCT reporting a significant reduction in ICS dose in the vitamin D group compared with controls, confirming observational findings. While bone health is optimised with serum 25OHD≥75 nmol/L, that is, vitamin D sufficiency, the thresholds for optimal immune, anti-inflammation and respiratory function are unknown, but believed to be higher. Hence, exploration of the impact of vitamin D on immune and inflammatory mechanistic pathways would enhance understanding of mechanisms of action.

In contrast to healthy children, vitamin D insufficiency is highly prevalent year-round in children with asthma, peaking in winter. In order to prevent the well-documented September asthma epidemic associated with URTIs, a rapid increase in, and maintenance of, serum 25OHD over the fall and winter is crucial. A single oral bolus of 100 000 international unit (IU) vitamin D3 rapidly increases 25OHD levels in preschoolers, but are not sustained without a repeat bolus and daily supplementation. In our first pilot RCT, a single bolus of 100 000 IU was compared with a single placebo bolus, with both groups receiving daily 400 IU vitamin D3 for 6 months: the intervention significantly raised serum 25OHD with 100% versus 55% of preschool-aged children, respectively, achieving a sustained level ≥75 nmol/L at 3 months. Despite a modest further increase in 25OHD, attributed to daily supplementation, there was no significant group difference at 6 months, underlying the need for a repeat bolus. In our second pilot RCT, comparing two 100 000 IU vitamin D3 versus placebo boluses, 3.5 months apart, without daily supplementation, a rapid increase in serum 25OHD was observed 10 days postbolus; however, serum 25OHD returned to baseline levels, with no significant group difference at 3.5 months, underlying the need for daily supplementation. This is concordant with prior literature suggesting no sustained effect of bolus supplementation alone on serum 25OHD or health outcomes. In our pilot trials, only two participants in the intervention group had a serum 25OHD>250 nmol/L after the first or second bolus; however, this was not associated with hypercalciuria or hypercalcaemia and there were no cases of vitamin D toxicity (serum 25OHD>500 nmol/L). We concluded that two bolus doses of 100 000 IU, given 3.5 months apart, with daily supplements of 400 IU vitamin D3 would ensure a rapid and sustained increase of serum 25OHD. Although routinely used in Europe, safety data remain scarce, contributing additional safety data on 100 000 IU bolus use appears worthwhile.

The protocol of a placebo-controlled parallel-group triple-blind RCT to explore the impact of vitamin D3 supplementation on reducing exacerbations in preschoolers with viral-induced asthma is described herein, as per Standard Protocol Items: Recommendations for Interventional Trials guidelines (online supplementary file 1).
The trial has been designed with consideration of several key factors, namely (i) pragmatic enrolment of eligible children irrespective of atopy, phenotype and baseline serum 25OHD to facilitate implementation; (ii) timing of intervention in the fall and early winter, with study period continued throughout winter to coincide with the peak incidence of exacerbations and URTIs and seasonal decline in serum 25OHD; (iii) use of a safe, easily implementable intervention, to achieve a rapid and sustained rise in serum 25OHD, with bolus administration coinciding with usual clinic visits; (iv) ICS prescribed in all participants according to Canadian recommendations, a recent history of asthma exacerbations, and who are not at risk for vitamin D deficiency at baseline.

Hypothesis

We hypothesise that vitamin D₃ supplementation will reduce the number of exacerbations requiring OCS per child by 25%, versus placebo, in children aged 1–5 years with recurrent moderate or severe viral-induced asthma exacerbations, and who are not at risk for vitamin D deficiency at baseline.

METHODS AND DESIGNS

Study design

This is a multicentre, phase III, randomised, triple-blind, placebo-controlled, parallel-group trial comparing supplemental vitamin D₃ and placebo, both administered as adjunct to ICS (figure 1).

This study is conducted over 4 years (first participant recruited: 1 October 2018; estimated study completion: December 2022) at seven Canadian hospitals: Sainte-Justine University Hospital Centre (CHSU), McGill University Health Centre (MUHC), Sherbrooke University Hospital Centre, Quebec University Hospital Centre, Children’s Hospital of Eastern Ontario, Children’s Hospital London Health Sciences Centre and British Columbia Children’s Hospital. Additional sites will be enlisted, if needed.

Subjects

Children are eligible if they meet any of the following criteria: current intake/intention to use >400 IU/day of vitamin D supplement, or combined dietary and supplemental vitamin D intake that would exceed the recommended daily upper limit (ie, 2500 IU for children aged 1–3 years and 3000 IU for children aged 4–8 years) if combined with the intervention dose; extreme prematurity (<28 weeks gestation); no vitamin D supplementation if exclusively breastfed in the past 6 months; vitamin D restrictive diet; undernourished (body mass index (BMI)-for-age in children≥2 years of age, or either <2 years of age in those <2 years, less than the third percentile); recent (<1 year) refugees and immigrants from regions at high risk of rickets; other chronic number of asthma-related ED visits; (vii) is associated with de-intensification of ICS therapy and (viii) is cost-effective. This study will examine the intervention’s safety profile by assessing whether there is a group difference in the proportion of children with: clinically significant (ix) hypercalciauria and (x) hypercalcaemia; (xi) serum 25OHD<250 nmol/L and (xii) adverse health events (AHE). It will also assess various exploratory outcomes.

Figure 1  Study design and participant flow through the 7±0.5 month study.
respiratory disease; diagnosed condition(s) or use of medication(s) that alter calcium or vitamin D absorption/metabolism and anticipated follow-up difficulties. Exclusions minimise the risk of including children with rickets and vitamin D deficiency without screening for serum 25OHD at baseline.

Study intervention

Intervention group participants receive a 2 mL oral bolus of 100000 IU vitamin D₃ (50000 IU cholecalciferol/mL) at randomisation in the fall or early winter, followed by a second 2 mL oral bolus of 100000 IU vitamin D₃ 3.5±0.5 months later. Participants also receive a total of five 50 mL coded bottles, containing a 400 IU vitamin D₃/mL preparation, to be administered at a dose of 1 mL/day using a dropper, for 7±0.5 months. Each bottle contains 50 daily doses. Placebo group participants receive an identical 2 mL placebo bolus, and daily dose of 1 mL placebo preparation, with administration timing identical to the intervention group.

Randomisation and masking

Using a computer-generated random list, stratified by site, children are allocated in a 1:1 ratio to the intervention or placebo group, using permuted block randomisation method to enhance concealment. Site-specific group allocation codes are held locally in a secure location with restricted access by each Site pharmacy, the CHUSJ Central Pharmacy and the independent biostatistician. The manufacturer (Euro-Pharm International Canada Inc., Montreal, QC Canada) provides the vitamin D₃ and placebo preparations, identical in appearance and taste, in coded latex-free bottles. The allocated treatment number, obtained at enrolment through a web-based randomisation system, Research Electronic Data Capture (REDCap), is forwarded to the Site pharmacy, which prepares the bolus in a coded syringe and the coded daily dose bottles, in masked kits. Research personnel administer orally the coded bolus dose to participants and provide daily dose bottles. Treatment compliance is ascertained by confirmation of bolus retention and pharmacy weighing of returned bottles. All participants, parents, research personnel, physicians and analysts involved in the trial are blinded to group allocation; only pharmacists are unblinded. At study endpoint, parents, physicians and research personnel are asked to guess the child’s group allocation. Efficacy and safety analyses will be performed under allocation concealment, with unblinding after trial completion and primary outcome analysis.

Cointerventions

Following Canadian guidelines, daily ICS or pre-emptive high-dose ICS with/without additional therapies, as per clinical judgement, is required at randomisation. Where calcium intake is identified as insufficient via dietary recall, dietary change or calcium supplements sufficient to meet the daily calcium Estimated Average Requirement (500 mg for children 1–3 years; 800 mg for children 4–8 years) is recommended.

Study procedures

Screening

Potentially eligible children are approached and screened for enrolment in asthma, chest or allergy clinics, asthma education centres, EDs and hospital units at participating sites from April to January; a successful strategy in previous trials. Advertisements may be placed in health institutions, newspapers, social media and online, where parents are invited to complete an online screening form and, if eligible and interested, to solicit a phone appointment with the research team to confirm eligibility, explain the study and schedule the randomisation visit.

Randomisation and follow-up contact visits

Randomisation occurs between 1 September and 31 January, with a 7-month follow-up. Participants attend three research visits (randomisation, 3.5±0.5 months, and 7±0.5 months) and receive six follow-up phone calls (7±3 days after each bolus, then monthly). Each contact serves to screen for AHeEs; inquire about recent exacerbations and URTIs, related parental work absenteeism and expenses, and concomitant medication use; and remind parents to complete questionnaires and collect a nasal swab during events (table 1).

Covariates

At baseline, skin colour is assessed using a visual adaptation of the validated Fitzpatrick scale. A blood sample is also drawn for a subsequent analysis of specific serum IgE (Phadiatop + Fx5 food allergen mix or equivalent). A nasal secretion sample is taken at randomisation and 3.5±0.5 months using a paediatric flocked mid-turbinate swab, placed in a tube containing 1 mL Universal Transport Medium (Copan Italia, Brescia, Italy), and stored at −80°C before quantification of the number and type of viruses using PCR analysis (Research St. Joseph’s, Hamilton, ON Canada). At each visit, height and weight are measured, and dietary and sun exposure questionnaires, are completed.

During an event

During a flare-up or URTI, parents are instructed to collect a nasal swab and complete: (1) the validated 17-item Asthma Flare-up Diary for Young Children (ADYC) daily throughout the event to document symptoms and, at the end of the event, both the (2) validated 21-item Effect of a Child’s Asthma flare-up on Parents (ECAP) questionnaire to measure parental quality of life and (3) summary-of-event form to capture healthcare utilisation, including hospital/pharmacy name. Parent collection of nasal swabs has been shown to be comparable to physician collection. Nasal swabs are frozen at −20°C until delivered (courier or in person) to the recruitment site and stored at −80°C prior to PCR analysis. Reminders containing instructions with links to complete online...
<table>
<thead>
<tr>
<th>Table 1  Study timeline and procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinic visits</strong></td>
</tr>
<tr>
<td>Randomisation</td>
</tr>
<tr>
<td>Blood and urine samples</td>
</tr>
<tr>
<td>Asthma phenotype and treatment</td>
</tr>
<tr>
<td>Sun exposure questionnaire, anthropometry</td>
</tr>
<tr>
<td>Skin colour ( Fitzpatrick scale)</td>
</tr>
<tr>
<td>Atopy (serum IgE)</td>
</tr>
<tr>
<td>Dietary intake (vitamin D, Calcium)</td>
</tr>
<tr>
<td>Weighting of daily vitamin D bottles</td>
</tr>
<tr>
<td>Dispensing and/or exchange of parent questionnaires</td>
</tr>
<tr>
<td>Nasal swab</td>
</tr>
<tr>
<td>Adverse health events</td>
</tr>
<tr>
<td>URTIs, exacerbations, medications, acute care visits or hospitalisations</td>
</tr>
<tr>
<td>Daily vitamin D supplement compliance</td>
</tr>
<tr>
<td><strong>Home visits</strong></td>
</tr>
<tr>
<td>Urine samples</td>
</tr>
<tr>
<td>Blood samples†</td>
</tr>
<tr>
<td><strong>Telephone contacts</strong></td>
</tr>
<tr>
<td>Adverse health events</td>
</tr>
<tr>
<td>URTIs, exacerbations, medications, emergency visits or hospitalisations</td>
</tr>
<tr>
<td>Daily vitamin D supplement compliance</td>
</tr>
<tr>
<td><strong>During each asthma flare-up or URTI</strong></td>
</tr>
<tr>
<td>Asthma flare-up diary for young children71</td>
</tr>
<tr>
<td>Effect of a child's asthma flare-up on parents72</td>
</tr>
<tr>
<td>Summary of cold or asthma flare-up form</td>
</tr>
<tr>
<td>Nasal swab (parent-collected)</td>
</tr>
<tr>
<td><strong>Laboratory analyses</strong></td>
</tr>
<tr>
<td>Urinary calcium:creatinine ratio</td>
</tr>
<tr>
<td>Serum calcium, phosphorus and ALP</td>
</tr>
<tr>
<td>Serum 25-hydroxyvitamin D</td>
</tr>
</tbody>
</table>

(✓) refers to a specimen sampled but not routinely analysed unless specifically requested by the Site endocrinologist.

*The delay is counted since the second bolus at 3.5±0.5 months.

†In a subset of patients recruited in two institutions.

ALP, alkaline phosphatase; d, days; m, months; URTI, upper respiratory tract infection.
questionnaires are sent by SMS or email at randomisation then regularly throughout the study period.

Risk management
Clinical and biochemical AHEs are monitored throughout the study and will be reported for all patients at the end of the study. A urine sample is systematically collected and analysed for calcium:creatinine ratio five times, that is, at each visit and at 10±3 days following each bolus. A non-fasting venous blood sample is collected at each visit for all participants and, in a subset of consenting participants, of the CHUSJ and MUHC, systematically at 10±3 days following the first bolus for peripheral blood mononuclear cell extraction in the two sites (CHUSJ and MUHC) able to process these samples. Blood samples are obtained for four main purposes: (i) individual patient’s safety assessment (eg, serum calcium (Ca), phosphorus (Ph), alkaline phosphatase (ALP), parathormone); (ii) intervention safety (eg, as above and serum 25OHD); (iii) covariate documentation (eg, serum total and specific IgE) and (iv) exploratory outcomes (eg, gene expression).

Any abnormal calcium:creatinine value is interpreted as ‘clinically significant’ or ‘not clinically significant’ by the blinded Site endocrinologist. If ‘clinically significant’, a blood aliquot is obtained to measure serum Ca, Ph, ALP, or a repeat urine calcium:creatinine is analysed. Further investigation or action for individual patients (including interruption, cessation, or, with prior notification of Site investigator, unblinding of the study drug via pharmacy or by analysis of serum 25OHD) will be selected by the Site endocrinologist, if needed to ensure patient safety. To maintain blinding, serum 25OHD aliquots will be analysed following study completion, unless specifically requested by the site endocrinologist or Data Monitoring Safety Board due to patient safety concerns.

In addition, dietary and supplemental vitamin D intake is systematically monitored throughout the trial to ensure that excess intake is not occurring.

Outcomes
Primary outcome
The primary outcome, the number of asthma exacerbations requiring OCS per child (ie, within-patient) during the 7-month follow-up, is ascertained by parental report at each contact, and confirmed after the final visit (7±0.5 months) via medical and pharmacy records, with parental consent obtained at enrolment. The success of this strategy is demonstrated in previous trials,8 40 41 irrespective of attrition. OCS use is assumed when a patient was administered or prescribed ≥1 OCS dose for an asthma or asthma-like event.

Secondary outcomes
The mean number of URTIs will be quantified via PCR analysis of nasal swabs, collected by parents during an exacerbation. The $ADYC^{21}$ is used to ascertain the severity (sum of the daily score) and duration (cumulative number of days with symptoms) of symptoms, and the intensity of rescue $\beta_2$-agonist use (cumulative daily number of puffs), during an exacerbation. The $ECAP$ questionnaire72 will capture parental functional status during an exacerbation. The mean number of ED visits for asthma is captured via the parent-completed summary-of-event form and confirmed by medical records. Any step-up or step-down in ICS therapy is captured via physician questionnaire at each visit. The intervention cost will be determined by documenting: (i) family expenses during an exacerbation (ie, medications, ED visits, hospitalisations, work absenteeism and out-of-pocket expenses), captured via parent report at each contact; (ii) healthcare cost (ie, ED visits, hospitalisations, medications and physician visits) and (iii) intervention cost, determined through drug manufacturer, nursing time and facility resource.

Safety outcomes
The primary safety outcome, a ‘clinically significant’ hypercalciuria event, is based on the site endocrinologist’s clinical interpretation of urinary calcium:creatinine results exceeding pre-established laboratory standards.74 Similarly, a ‘clinically significant’ hypercalcaemia event is based on the site endocrinologist’s clinical interpretation of serum calcium results exceeding pre-established laboratory standards. Elevated serum 25OHD is defined as a value >250 nmol/L,64 measured at the CHUSJ Central Laboratory after study completion to maintain blinding. Serious and non-serious AHEs will be recorded at each contact in accordance with guidelines adopted by Health Canada.75

Exploratory outcomes
Several outcomes pertaining to immune, infection, inflammation, bone and genetic markers (including changes in gene expression) and lung function will be documented.

Data management and monitoring
The Applied Clinical Research Unit at CHUSJ will oversee randomisation, data management, progress monitoring and all analyses, including those for the Data Safety Monitoring Board (DSMB). REDCap66 will be used for online data entry and management. A combination of remote monitoring activities and routine monitoring visits are conducted to ensure that each Site adheres to the study protocol, Good Clinical Practice guidelines and data collection completeness.

Sample size calculation
Based on our previous data,8 the number of OCS per child is well approximated by a Poisson distribution. The mean number of events per interval ($\lambda$) was conservatively estimated at 0.55 OCS/child in our placebo arm (based on prorated event rates in preschoolers receiving daily/ pre-emptive ICS in previous trials).8–16 A sample size of 400 children per arm will provide 80% power with a two-tailed alpha of 5% to detect a 25% relative reduction in the mean number of events (ie, $\lambda=0.55$ in the placebo, vs
λ=0.4125 in the intervention, group). This is a conserva-
tive estimate, given the observed rate ratio of 0.64 (95%CI 0.46 to 0.90) in a 2016 meta-analysis. Allowing for 10% attrition, we aim to recruit 865 children (432/arm).

Statistical analysis
Primary outcome
An intention-to-treat analysis will be carried out with all
randomised children by treatment group. The primary
outcome will be analysed using a Poisson regression
model (including parameters for site stratification)
to compute the rate ratio (incidence) for comparing the
mean (within-patient) number of OCS per child during
the 7-month follow-up, with over-dispersion and offset
variable for variations in person-time. A formal interim
analysis will be performed when approximately 50% have
been enrolled and completed follow-up. The DSMB will
review the interim safety and efficacy data. Interim and
final analyses will be adjusted to maintain an overall type
I error rate, based on Lan and DeMet’s implementation
of the O’Brien-Fleming grouped sequential stopping
boundary. This implementation will permit early stopping
only for strong positive or negative effects and maintains
nearly all the nominal power for the final analysis. Seven
subgroup analyses are planned on baseline: serum 25OHD
(<75 vs ≥75 nmol/L), ICS therapy (pre-emptive vs daily),
asthma phenotype (viral-induced vs multitrigger), sex
(male/female), atopy (specific multiallergen IgE
induced vs multitrigger), sex
(male/female), atopy (specific multiallergen IgE
<0.35 or ≥0.35 kUa/L), BMI (Z-score ≤2 vs >2SD),68 and skin
colour (five categories).67

Secondary and safety outcomes
The mean number of laboratory-confirmed viral URTIs
will be compared between groups using a negative binom-
ial model that includes a shape parameter and site strat-
ification. Symptom severity during an exacerbation will
be compared between groups using a generalised linear
regression model, adjusting for event clustering in individ-
uals with an offset variable for variations in person-time,
if relevant. Similar analyses will be carried out for symptom
duration, intensity of rescue β₂-agonist use, and parental
functional status, during an exacerbation. The Mantel-
Haenszel method, stratified by site, will serve to compare
categorical outcomes, including the number of children
with ≥1 episode of clinically significant hypercalciuria,
hypercalcaemia, elevated serum 25OHD, and AHEs; and
Poisson regression to compare the mean number of ED
visits. No adjustment for multiple outcomes is planned.
The cost-effectiveness of the intervention will be eval-
uated using standard trial-based economic evaluation
methods, employing a nested loop of imputation of
missing values (due to attrition), regression (to adjust for
baseline variables) and bootstrapping (to estimate uncer-
tainty).72 The main outcome of the economic evaluation
will be the incremental costs per exacerbation avoided.
The main analysis will adopt a public health payer per-
pective, where direct medical costs will be considered.
A secondary analysis, adopting a societal perspective,
with the unique research code, prior to transfer and storage at the CHUSJ biobank, with access restricted to authorised personnel.

There are two, though extremely low, theoretical risks with vitamin D supplementation in Canadian children: hypocalcaemia, secondary to a rapid increase in bone remodelling at baseline in the condition where the participant presents with an undiagnosed active rickets; and hypercalcaemia/calcium, due to enhancing effects of vitamin D on intestinal absorption of calcium. Our trial design has incorporated strategies to mitigate risk. We are excluding at enrolment patients at high risk of vitamin D deficiency and are routinely evaluating calcium and vitamin D dietary intake, both to exclude the rare child with rickets (Canadian annual incidence 1.6–2.9/100 000 children), in whom vitamin D, without calcium, supplementation could lead to hypocalcaemia. In the first hypothetical case of rickets, ALP levels should also be elevated and be a second flag to exclude this child from the study. Any toxicity in vitamin D is mediated via elevated serum calcium (with normal or elevated serum phosphorous and normal or low ALP); if serum calcium is normal, there is no clinical risk of vitamin D toxicity to the individual. To minimise the risk of hypercalcaemia (which could signal vitamin D intoxication), we have selected a bolus dose routinely recommended in France, with no documented adverse effects, are excluding children with recent excessive vitamin D supplementation, are systematically screening urine calcium:creatinine (the most sensitive marker of elevated serum calcium) and serum biomarkers (ALP, calcium and phosphorous) at randomisation, with urine screening periodically throughout the trial, and implemented a process whereby all abnormal values are reviewed by the Site endocrinologist for clinical interpretation and management where indicated. Finally, as we expect a fair proportion of enrolled children to have vitamin D insufficiency (ie, 25–75 nmol/L) at study entry, all participants will be advised at the end of the study if their usual (dietary and supplemental) vitamin D intake was below recommendations, and provided general dietary advice to meet the Canadian recommended daily intake.

Serious adverse drug reactions will be reported to the Therapeutic Products Directorate (Health Canada) where they are ‘unexpected’ and the investigator deems there is a reasonable suspected causal relationship to the treatment, or, they are ‘expected’ and there is an increase in the incidence or the severity is of clinical importance.

An independent DSMB, comprised of relevant experts (paediatric respiratory medicine, paediatric endocrinology, biostatistics and vitamin D) has been established, with terms of reference; it periodically reviews the occurrence of any ‘clinically significant’ abnormal hypercalciuria/calcemia results and the number and distribution of AHEs, with notification of serious unexpected AHEs provided within 48 hours of their reporting.

**Implementation and dissemination**

This trial employs pragmatic patient selection without serum 25OHD prescreening and intervention to maximise subsequent implementation into practice. If effective in reducing short-term morbidity, this approach would be readily implementable and could markedly influence asthma management in high-morbidity preschoolers.

No participant identifiers will be used in the dissemination of this research. Results will be disseminated to the medical community via national/international conferences and publications in peer-reviewed journals, and to families of preschoolers with asthma by involving parents–partners in the disseminating plan.

**Author affiliations**

1. Priority Research Centre Grow Up Well, School of Medicine & Public Health, Faculty of Health, The University of Newcastle, Callaghan, New South Wales, Australia
2. Department of Social & Preventive Medicine, University of Montreal, Montreal, Quebec, Canada
3. Clinical Research and Knowledge Transfer Unit on Childhood Asthma, Research Centre, CHU Sainte-Justine, Montreal, Quebec, Canada
4. Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada
5. Pediatric Endocrinology Service, CHU Sainte-Justine, Montreal, Quebec, Canada
6. Department of Nutrition, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada
7. Research Centre, CHU Sainte-Justine, Montreal, Quebec, Canada
8. School of Public Health, University of Montreal, Montreal, Quebec, Canada
9. Department of Physiology, McGill University, Montreal, Quebec, Canada
10. Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
11. Euro-Pharm International Canada Inc, Montreal, Quebec, Canada
12. Department of Pediatrics, Montreal Children’s Hospital, Montreal, Quebec, Canada
13. Department of Pediatrics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
14. Department of Pediatrics, Centre Mère-Enfant du CHU de Québec, Quebec City, Quebec, Canada
15. Division of Allergy and Immunology, Department of Pediatrics, Université de Sherbrooke, Sherbrooke, Quebec, Canada
16. Department of Pediatrics, British Columbia Children’s Hospital, Vancouver, British Columbia, Canada
17. Department of Pediatrics, Children’s Hospital of Eastern Ontario, Ottawa, Ontario, Canada

**Twitter** Megan E Jensen @DrMeganEJensen

**Contributors** FMD designed the study protocol, secured funding and oversees the project. MEJ wrote the first manuscript draft and, along with GM, was involved in the study design and dietary assessment. NA is overseeing the safety assessment. BM is responsible for the randomisation, data management and statistical analysis. MS is responsible for the economic analysis. JHW is responsible for the gene expression analysis. AK is responsible for the development and provision of the placebo and high-dose vitamin D supplement. All other coauthors (SMT, RA, DEB, PD, CL, CY and DR) participated in study design, approved the study protocol and manuscript, and are responsible for conducting the study at their respective sites. Authorship eligibility on resulting manuscripts will follow standard guidelines.

**Funding** This project is funded by a grant awarded through a peer-reviewed process by the Canadian Institutes of Health Research, 160 Elgin Street, Ottawa, ON, K1A 0W9, Canada (grant number #153252).

**Competing interests** By partnership agreement, Euro-Pharm International Canada Inc. (Montreal, QC Canada), and their representative (Ali Khamesian) donated all vitamin D study preparations. Dr Khamesian is responsible for the formulation of the placebo and high-dose vitamin D preparation; however, neither Dr Khamesian, nor Euro-Pharm International Canada Inc., had any input into other aspects of study design, and will have no involvement in analysis or interpretation of results. The authors have no competing interests.

**Patient consent for publication** Not required.
REFERENCES


